AIRE (Autoimmune regulator) variants and mutations
AIRE (also known as Autoimmune regulator) is a human protein-coding gene encoding an autoimmune regulator protein. It promotes immune tolerance by driving expression of tissue-restricted antigens in thymic medullary epithelial cells, helping eliminate self-reactive T cells. Biallelic loss-of-function variants cause autoimmune polyendocrine syndrome type 1. This analysis covers 1,149 AIRE variants and mutations. Of these, 83% have computational variant effect predictions. Disease context includes autoimmune polyendocrine syndrome type 1, Autoimmune polyendocrinopathy type 1, and autoimmune polyendocrinopathy. Example AIRE variants include M1K, M1L, and M1R.
Variant analysis overview
- Gene: AIRE
- Protein: Autoimmune regulator
- UniProt accession: O43918
- Organism: Homo sapiens
- Variants analyzed: 1149
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 890 unspecified-consequence records; 2 in-frame insertions; 148 missense variants; 17 frameshift variants; 82 synonymous variants; 5 stop-gained variants; 2 in-frame deletions; 1 splice-region variants; 1 substitution
- Prediction scores: 954 variants have prediction scores (83% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: autoimmune polyendocrine syndrome type 1, Autoimmune polyendocrinopathy type 1, autoimmune polyendocrinopathy, rheumatoid arthritis, hereditary disease, neurodegenerative disease, retinal disorder, adrenocortical insufficiency, Genetic chronic primary adrenal insufficiency, primary adrenal insufficiency, familial isolated hypoparathyroidism due to impaired PTH secretion, immunodeficiency disease.
Protein structure and variant hotspots
- Protein features: 2 domains.
- Structural context: 523 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable AIRE variants
Examples include M1K, M1L, M1R, M1T, M1V, p.Met1 Ala2insAspTyrLysAspAspAsp, A2S, A2T. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1K (p.Met1Lys), rs2146374989, ClinGen CA410422910, ClinVar RCV001783349, MetaLR 0.64, MetaSVM -0.21, Pathogenic, Polyglandular autoimmune syndrome, type 1
- M1L (p.Met1Leu), rs121434258, ClinGen CA116147, ClinVar RCV000003478, ClinVar RCV001091469, MetaLR 0.44, MetaSVM -0.46, Pathogenic, not provided; Polyglandular autoimmune syndrome, type 1
- M1R (p.Met1Arg), rs2146374989, ClinGen CA410422912, ClinVar RCV002007164, MetaLR 0.64, MetaSVM -0.21, Pathogenic, Polyglandular autoimmune syndrome, type 1
- M1T (p.Met1Thr), rs2146374989, ClinGen CA410422911, ClinVar RCV003064634, MetaLR 0.64, MetaSVM -0.21, Pathogenic, Polyglandular autoimmune syndrome, type 1
- M1V (p.Met1Val), rs121434258, ClinGen CA10051456, ClinVar RCV000666118, ClinVar RCV001027543, MetaLR 0.44, MetaSVM -0.46, Pathogenic, Inherited Immunodeficiency Diseases; Polyglandular autoimmune syndrome, type 1
- p.Met1 Ala2insAspTyrLysAspAspAsp, gnomAD 21-44286008-T-TGG, CADD 5.30
- A2S (p.Ala2Ser), gnomAD 21-44286010-G-T, REVEL 0.14, MetaLR 0.45
- A2T (p.Ala2Thr), gnomAD 21-44286010-G-A, REVEL 0.16, MetaLR 0.56
- A2E (p.Ala2Glu), gnomAD 21-44286011-C-A, REVEL 0.20, MetaLR 0.58
- A2A (p.Ala2Ala), gnomAD 21-44286012-G-A, CADD 7.13
- T3A (p.Thr3Ala), Ensembl rs2146374993, REVEL 0.12, AlphaMissense 0.05
- T3M (p.Thr3Met), TOPMed rs1313064637, gnomAD rs1313064637, REVEL 0.14, MetaLR 0.48
- T3P (p.Thr3Pro), rs2146374993, ClinGen CA410422922, ClinVar RCV002717510, AlphaMissense 0.05, MetaLR 0.45, Uncertain significance, Inborn genetic diseases
- T3K (p.Thr3Lys), gnomAD 21-44286014-C-A, REVEL 0.23, MetaLR 0.48
- T3T (p.Thr3Thr), rs749029660, gnomAD 21-44286015-G-A, CADD 4.53
- D4A (p.Asp4Ala), rs2146375006, ClinGen CA410422930, ClinVar RCV002763264, AlphaMissense 0.29, MetaLR 0.84, Uncertain significance, Inborn genetic diseases
- D4E (p.Asp4Glu), ExAC rs768696010, TOPMed rs768696010, gnomAD rs768696010, REVEL 0.29, MetaLR 0.40, Likely benign
- D4N (p.Asp4Asn), rs1014398252, ClinGen CA321787729, ClinVar RCV000801078, TOPMed rs1014398252, REVEL 0.43, MetaLR 0.84, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- D4V (p.Asp4Val), rs2146375006, ClinGen CA410422932, ClinVar RCV001902807, ClinVar RCV005841870, AlphaMissense 0.29, MetaLR 0.84, Uncertain significance, Inborn genetic diseases; Polyglandular autoimmune syndrome, type 1
- D4R (p.Asp4Arg), gnomAD 21-44286011-CGACG, CADD 20.30
- D4Y (p.Asp4Tyr), gnomAD 21-44286016-G-T, REVEL 0.63, MetaLR 0.85
- D4H (p.Asp4His), gnomAD 21-44286016-G-C, REVEL 0.58, MetaLR 0.85
- D4G (p.Asp4Gly), gnomAD 21-44286017-A-G, REVEL 0.57, MetaLR 0.83
- D4D (p.Asp4Asp), rs768696010, gnomAD 21-44286018-C-T, CADD 5.49
- A5L (p.Ala5Leu), rs2146375021, ClinGen CA2573157672, ClinVar RCV001920433, Ensembl rs2146375021, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- A5T (p.Ala5Thr), rs774168916, ClinGen CA10051459, ClinVar RCV002623446, ExAC rs774168916, REVEL 0.18, MetaLR 0.44, Uncertain significance, Polyglandular autoimmune syndrome, type 1; Inborn genetic diseases
- A5V (p.Ala5Val), gnomAD rs1236841505, REVEL 0.24, MetaLR 0.60
- A5S (p.Ala5Ser), gnomAD 21-44286019-G-T, REVEL 0.23, MetaLR 0.55
- A5E (p.Ala5Glu), gnomAD 21-44286020-C-A, REVEL 0.32, MetaLR 0.71
- A5A (p.Ala5Ala), gnomAD 21-44286021-G-T, CADD 0.90
- A6P (p.Ala6Pro), gnomAD rs1358819740, REVEL 0.38, MetaLR 0.57
- A6V (p.Ala6Val), gnomAD rs1304366953, REVEL 0.14, MetaLR 0.48
- A6T (p.Ala6Thr), gnomAD 21-44286022-G-A, REVEL 0.15, MetaLR 0.53
- A6S (p.Ala6Ser), gnomAD 21-44286022-G-T, REVEL 0.17, MetaLR 0.46
- A6G (p.Ala6Gly), gnomAD 21-44286023-C-G, REVEL 0.18, MetaLR 0.46
- A6E (p.Ala6Glu), gnomAD 21-44286023-C-A, REVEL 0.28, MetaLR 0.46
- A6A (p.Ala6Ala), rs1228505896, gnomAD 21-44286024-G-C, CADD 3.81
- L7V (p.Leu7Val), Ensembl rs2040477515, REVEL 0.55, MetaLR 0.70
- L7I (p.Leu7Ile), gnomAD 21-44286025-C-A, REVEL 0.47, MetaLR 0.82
- L7P (p.Leu7Pro), gnomAD 21-44286026-T-C, REVEL 0.75, MetaLR 0.90
- L7L (p.Leu7Leu), gnomAD 21-44286027-A-T, CADD 4.99
- R8C (p.Arg8Cys), rs1231469574, ClinGen CA410422952, ClinVar RCV000668219, ClinVar RCV000710495, REVEL 0.75, MetaLR 0.87, Conflicting interpretations, not provided; Polyglandular autoimmune syndrome, type 1; Retinal disorder
- R8H (p.Arg8His), rs1206933109, ClinGen CA410422953, ClinVar RCV003636331, TOPMed rs1206933109, REVEL 0.72, MetaLR 0.87, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- R8L (p.Arg8Leu), NCI-TCGA TCGA novel, REVEL 0.76, MetaLR 0.87, Variant assessed as somatic; moderate impact.
- R8S (p.Arg8Ser), gnomAD 21-44286028-C-A, REVEL 0.70, MetaLR 0.87
- R8G (p.Arg8Gly), gnomAD 21-44286028-C-G, REVEL 0.72, MetaLR 0.87
- R8P (p.Arg8Pro), gnomAD 21-44286029-G-C, REVEL 0.78, MetaLR 0.87
- R8R (p.Arg8Arg), rs2040477613, gnomAD 21-44286030-C-A, CADD 7.74
- R9P (p.Arg9Pro), rs1057517878, ClinGen CA16043166, ClinVar RCV000414619, Ensembl rs1057517878, AlphaMissense 0.10, MetaLR 0.49, Likely pathogenic, not provided
- R9Q (p.Arg9Gln), Ensembl rs1057517878, REVEL 0.26, AlphaMissense 0.10, Likely pathogenic
- R9W (p.Arg9Trp), rs1942959342, ClinGen CA410422957, ClinVar RCV001267736, Ensembl rs1942959342, REVEL 0.48, MetaLR 0.74, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- R9G (p.Arg9Gly), gnomAD 21-44286016-G-GAC, CADD 22.40
- R9R (p.Arg9Arg), gnomAD 21-44286031-C-A, CADD 8.41
- R9L (p.Arg9Leu), gnomAD 21-44286032-G-T, REVEL 0.40, MetaLR 0.61
- L10T (p.Leu10Thr), gnomAD 21-44286013-A-ACG, CADD 14.20
- L10I (p.Leu10Ile), gnomAD 21-44286034-C-A, REVEL 0.43, MetaLR 0.83
- L10L (p.Leu10Leu), rs1024577400, gnomAD 21-44286036-T-C, CADD 4.09
- L11M (p.Leu11Met), gnomAD 21-44286037-C-A, REVEL 0.58, MetaLR 0.87
- L11P (p.Leu11Pro), gnomAD 21-44286038-T-C, REVEL 0.89, MetaLR 0.89
- L11L (p.Leu11Leu), gnomAD 21-44286039-G-A, CADD 9.51
- R12G (p.Arg12Gly), rs1131691636, ClinGen CA410422971, ClinVar RCV000493760, Ensembl rs1131691636, REVEL 0.76, MetaLR 0.80, Likely pathogenic, not provided
- R12W (p.Arg12Trp), gnomAD 21-44286040-A-T, REVEL 0.72, MetaLR 0.83
- R12M (p.Arg12Met), gnomAD 21-44286041-G-T, REVEL 0.64, MetaLR 0.82
- R12K (p.Arg12Lys), gnomAD 21-44286041-G-A, REVEL 0.28, MetaLR 0.44
- R12R (p.Arg12Arg), gnomAD 21-44286042-G-A, CADD 12.40
- R12S (p.Arg12Ser), gnomAD 21-44286042-G-T, REVEL 0.72, MetaLR 0.80
- L13V (p.Leu13Val), gnomAD 21-44286043-C-G, REVEL 0.53, MetaLR 0.81
- L13M (p.Leu13Met), gnomAD 21-44286043-C-A, REVEL 0.51, MetaLR 0.82
- L13L (p.Leu13Leu), gnomAD 21-44286043-C-T, CADD 11.80
- L13P (p.Leu13Pro), gnomAD 21-44286044-T-C, REVEL 0.74, MetaLR 0.83
- H14P (p.His14Pro), rs2517875582, ClinGen CA410422987, ClinVar RCV003636995, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- H14Y (p.His14Tyr), gnomAD 21-44286046-C-T, REVEL 0.21, MetaLR 0.50
- H14N (p.His14Asn), gnomAD 21-44286046-C-A, REVEL 0.35, MetaLR 0.60
- H14R (p.His14Arg), gnomAD 21-44286047-A-G, REVEL 0.42, MetaLR 0.69
- H14Q (p.His14Gln), gnomAD 21-44286048-C-A, REVEL 0.52, MetaLR 0.69
- H14H (p.His14His), rs2146375067, gnomAD 21-44286048-C-T, CADD 10.00
- R15C (p.Arg15Cys), rs179363875, ClinGen CA219205, ClinVar RCV000059059, ClinVar RCV000666777, REVEL 0.86, MetaLR 0.87, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- R15G (p.Arg15Gly), rs179363875, ClinGen CA410422992, ClinVar RCV001988247, Ensembl rs179363875, REVEL 0.84, MetaLR 0.87, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- R15H (p.Arg15His), rs179363876, ClinGen CA410422994, ClinVar RCV001283785, TOPMed rs179363876, REVEL 0.82, MetaLR 0.87, Pathogenic/Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- R15L (p.Arg15Leu), rs179363876, ClinGen CA219207, ClinVar RCV000059060, ClinVar RCV001378939, REVEL 0.92, MetaLR 0.87, Pathogenic/Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- R15S (p.Arg15Ser), gnomAD 21-44286049-C-A, REVEL 0.83, MetaLR 0.87
- R15P (p.Arg15Pro), gnomAD 21-44286050-G-C, REVEL 0.89, MetaLR 0.87
- R15R (p.Arg15Arg), gnomAD 21-44286051-C-T, CADD 14.20
- T16A (p.Thr16Ala), rs1340739925, ClinGen CA410422996, ClinVar RCV003045755, gnomAD rs1340739925, REVEL 0.78, MetaLR 0.86, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- T16M (p.Thr16Met), rs179363877, ClinGen CA219209, ClinVar RCV000059061, ClinVar RCV001037856, REVEL 0.87, MetaLR 0.87, Pathogenic, Polyglandular autoimmune syndrome, type 1
- T16R (p.Thr16Arg), rs179363877, ClinVar RCV004587984, REVEL 0.86, MetaLR 0.87, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- T16K (p.Thr16Lys), gnomAD 21-44286053-C-A, REVEL 0.85, MetaLR 0.87
- T16T (p.Thr16Thr), rs2146375080, gnomAD 21-44286054-G-C, CADD 4.26
- E17D (p.Glu17Asp), rs1036995518, ClinGen CA321787731, ClinVar RCV001069312, gnomAD rs1036995518, REVEL 0.63, MetaLR 0.85, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- E17* (p.Glu17Ter), gnomAD 21-44286055-G-T, CADD 40.00
- E17Q (p.Glu17Gln), gnomAD 21-44286055-G-C, REVEL 0.62, MetaLR 0.86
- E17G (p.Glu17Gly), gnomAD 21-44286056-A-G, REVEL 0.85, MetaLR 0.87
- E17V (p.Glu17Val), gnomAD 21-44286056-A-T, REVEL 0.87, MetaLR 0.87
- I18F (p.Ile18Phe), TOPMed rs1237111503, gnomAD rs1237111503, REVEL 0.90, MetaLR 0.92
- I18M (p.Ile18Met), rs2517875605, ClinGen CA410423013, ClinVar RCV002894335, Likely pathogenic, Polyglandular autoimmune syndrome, type 1
- I18V (p.Ile18Val), TOPMed rs1237111503, gnomAD rs1237111503, REVEL 0.71, MetaLR 0.91
- I18T (p.Ile18Thr), gnomAD 21-44286059-T-C, REVEL 0.93, MetaLR 0.92
- I18I (p.Ile18Ile), gnomAD 21-44286060-C-T, CADD 10.10
- A19E (p.Ala19Glu), TOPMed rs1456062309, gnomAD rs1456062309, REVEL 0.70, MetaLR 0.91
- A19T (p.Ala19Thr), rs1555871798, ClinGen CA410423016, ClinVar RCV000669082, Ensembl rs1555871798, REVEL 0.73, MetaLR 0.88, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- A19V (p.Ala19Val), TOPMed rs1456062309, gnomAD rs1456062309, REVEL 0.73, MetaLR 0.89
- A19S (p.Ala19Ser), gnomAD 21-44286061-G-T, REVEL 0.47, MetaLR 0.84
- A19A (p.Ala19Ala), gnomAD 21-44286063-G-T, CADD 1.07
- V20E (p.Val20Glu), rs1291820513, TOPMed rs1291820513, AlphaMissense 0.59, MetaLR 0.79, Variant assessed as somatic; moderate impact.
- V20M (p.Val20Met), Ensembl rs2146375105, REVEL 0.27, MetaLR 0.42
- V20L (p.Val20Leu), gnomAD 21-44286064-G-T, REVEL 0.27, MetaLR 0.62
- V20A (p.Val20Ala), gnomAD 21-44286065-T-C, REVEL 0.39, MetaLR 0.69
- V20V (p.Val20Val), gnomAD 21-44286066-G-A, CADD 9.62
- A21S (p.Ala21Ser), gnomAD rs1253173341, REVEL 0.80, MetaLR 0.93
- A21V (p.Ala21Val), rs179363886, ClinGen CA199074, ClinVar RCV000059062, ClinVar RCV000169178, REVEL 0.87, MetaLR 0.93, Pathogenic, not provided; Polyglandular autoimmune syndrome, type 1
- A21P (p.Ala21Pro), gnomAD 21-44286065-TG-T, CADD 25.10
- A21T (p.Ala21Thr), gnomAD 21-44286067-G-A, REVEL 0.86, MetaLR 0.93
- A21D (p.Ala21Asp), gnomAD 21-44286068-C-A, REVEL 0.86, MetaLR 0.93
- A21A (p.Ala21Ala), rs371796437, gnomAD 21-44286069-C-T, CADD 1.41
- V22G (p.Val22Gly), rs2517875621, ClinGen CA410423035, ClinVar RCV003226669, Uncertain significance, not specified
- V22M (p.Val22Met), ExAC rs773373725, TOPMed rs773373725, gnomAD rs773373725, REVEL 0.54, MetaLR 0.83
- p.Val22 Asp23del, rs752303080, gnomAD 21-44286068-CCGTG, CADD 20.40
- V22L (p.Val22Leu), gnomAD 21-44286070-G-C, REVEL 0.44, MetaLR 0.76
- V22E (p.Val22Glu), gnomAD 21-44286071-T-A, REVEL 0.78, MetaLR 0.87
- V22A (p.Val22Ala), gnomAD 21-44286071-T-C, REVEL 0.54, MetaLR 0.79
- V22V (p.Val22Val), rs1028887337, gnomAD 21-44286072-G-T, CADD 11.70
- D23G (p.Asp23Gly), rs2040478254, ClinGen CA410423039, ClinVar RCV001880876, Ensembl rs2040478254, AlphaMissense 0.28, MetaLR 0.86, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- D23N (p.Asp23Asn), rs975525470, ClinGen CA321787734, ClinVar RCV002006973, TOPMed rs975525470, REVEL 0.58, MetaLR 0.78, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- D23Y (p.Asp23Tyr), gnomAD 21-44286073-G-T, REVEL 0.80, MetaLR 0.85
- D23H (p.Asp23His), gnomAD 21-44286073-G-C, REVEL 0.72, MetaLR 0.83
- D23D (p.Asp23Asp), gnomAD 21-44286075-C-T, CADD 13.10
- S24C (p.Ser24Cys), gnomAD 21-44286076-A-T, REVEL 0.32, MetaLR 0.63
- S24G (p.Ser24Gly), gnomAD 21-44286076-A-G, REVEL 0.40, MetaLR 0.66
- S24N (p.Ser24Asn), gnomAD 21-44286077-G-A, REVEL 0.43, MetaLR 0.74
- S24I (p.Ser24Ile), gnomAD 21-44286077-G-T, REVEL 0.65, MetaLR 0.76
- S24S (p.Ser24Ser), rs1365198075, gnomAD 21-44286078-C-T, CADD 12.30
- S24R (p.Ser24Arg), gnomAD 21-44286078-C-A, REVEL 0.43, MetaLR 0.77
- A25D (p.Ala25Asp), TOPMed rs1398217393, gnomAD rs1398217393, REVEL 0.61, MetaLR 0.83, Uncertain significance
- A25G (p.Ala25Gly), rs1398217393, ClinGen CA410423054, ClinVar RCV003364652, TOPMed rs1398217393, REVEL 0.50, MetaLR 0.82, Uncertain significance, Inborn genetic diseases
- A25P (p.Ala25Pro), rs761025044, ClinGen CA10051464, ClinVar RCV001245440, ExAC rs761025044, REVEL 0.51, MetaLR 0.78, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- A25T (p.Ala25Thr), ExAC rs761025044, TOPMed rs761025044, gnomAD rs761025044, REVEL 0.42, MetaLR 0.77, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- A25S (p.Ala25Ser), gnomAD 21-44286079-G-T, REVEL 0.43, MetaLR 0.80
- A25V (p.Ala25Val), gnomAD 21-44286080-C-T, REVEL 0.44, MetaLR 0.72
- A25A (p.Ala25Ala), gnomAD 21-44286081-C-A, CADD 13.20
- F26S (p.Phe26Ser), gnomAD 21-44286081-CT-C, CADD 24.30
- F26L (p.Phe26Leu), gnomAD 21-44286082-T-C, REVEL 0.84, MetaLR 0.92
- F26I (p.Phe26Ile), gnomAD 21-44286082-T-A, REVEL 0.84, MetaLR 0.93
- F26F (p.Phe26Phe), rs1443107040, gnomAD 21-44286084-C-T, CADD 10.40
- P27A (p.Pro27Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- P27T (p.Pro27Thr), gnomAD 21-44286085-C-A, REVEL 0.92, MetaLR 0.95
- P27S (p.Pro27Ser), gnomAD 21-44286085-C-T, REVEL 0.91, MetaLR 0.95
- P27Q (p.Pro27Gln), gnomAD 21-44286086-C-A, REVEL 0.90, MetaLR 0.96
- L28P (p.Leu28Pro), rs179363878, ClinGen CA219211, ClinVar RCV000059063, ClinVar RCV000810303, REVEL 0.88, MetaLR 0.89, Pathogenic/Likely pathogenic, not provided; Polyglandular autoimmune syndrome, type 1
- L28M (p.Leu28Met), gnomAD 21-44286088-C-A, REVEL 0.59, MetaLR 0.89
- L28L (p.Leu28Leu), gnomAD 21-44286090-G-A, CADD 9.51
- L29P (p.Leu29Pro), rs179363879, ClinGen CA219213, ClinVar RCV000059064, ClinVar RCV003329239, REVEL 0.88, MetaLR 0.91, Pathogenic, Polyglandular autoimmune syndrome, type 1
- L29M (p.Leu29Met), gnomAD 21-44286091-C-A, REVEL 0.58, MetaLR 0.87
- L29L (p.Leu29Leu), gnomAD 21-44286091-C-T, CADD 10.60
- H30Q (p.His30Gln), ExAC rs754316070, TOPMed rs754316070, gnomAD rs754316070, REVEL 0.47, MetaLR 0.80, Likely benign
- H30Y (p.His30Tyr), gnomAD rs1385282121, REVEL 0.69, MetaLR 0.81, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- H30N (p.His30Asn), gnomAD 21-44286094-C-A, REVEL 0.71, MetaLR 0.84
- H30H (p.His30His), rs754316070, gnomAD 21-44286096-C-T, CADD 7.29
- A31S (p.Ala31Ser), gnomAD 21-44286097-G-T, REVEL 0.29, MetaLR 0.60
- A31E (p.Ala31Glu), gnomAD 21-44286098-C-A, REVEL 0.58, MetaLR 0.81
- A31V (p.Ala31Val), gnomAD 21-44286098-C-T, REVEL 0.50, MetaLR 0.80
- A31A (p.Ala31Ala), gnomAD 21-44286099-G-T, CADD 6.56
- L32L (p.Leu32Leu), gnomAD 21-44286100-C-T, CADD 9.01
- L32P (p.Leu32Pro), gnomAD 21-44286101-T-C, REVEL 0.82, MetaLR 0.94
- L32Q (p.Leu32Gln), gnomAD 21-44286101-T-A, REVEL 0.80, MetaLR 0.94
- A33G (p.Ala33Gly), gnomAD rs1256655851, REVEL 0.71, MetaLR 0.86
- A33T (p.Ala33Thr), ExAC rs755314503, gnomAD rs755314503, REVEL 0.69, MetaLR 0.87
- A33S (p.Ala33Ser), gnomAD 21-44286103-G-T, REVEL 0.64, MetaLR 0.87
- A33D (p.Ala33Asp), gnomAD 21-44286104-C-A, REVEL 0.78, MetaLR 0.86
- A33V (p.Ala33Val), gnomAD 21-44286104-C-T, REVEL 0.65, MetaLR 0.86
- A33A (p.Ala33Ala), rs3746964, gnomAD 21-44286105-T-C, CADD 3.94
- D34E (p.Asp34Glu), rs2517875684, ClinGen CA410423108, ClinVar RCV002802076, REVEL 0.68, MetaLR 0.93, Uncertain significance, Polyglandular autoimmune syndrome, type 1
- D34N (p.Asp34Asn), gnomAD rs1214972960, REVEL 0.63, MetaLR 0.93
- D34Y (p.Asp34Tyr), gnomAD rs1214972960, REVEL 0.81, MetaLR 0.93
- D34G (p.Asp34Gly), gnomAD 21-44286107-A-G, REVEL 0.86, MetaLR 0.94
- D34D (p.Asp34Asp), gnomAD 21-44286108-C-T, CADD 12.50
- H35Q (p.His35Gln), gnomAD rs2040478756, REVEL 0.53, MetaLR 0.84
- H35R (p.His35Arg), gnomAD rs1273452030, REVEL 0.54, MetaLR 0.78
- H35N (p.His35Asn), gnomAD 21-44286109-C-A, REVEL 0.60, MetaLR 0.84
- H35Y (p.His35Tyr), gnomAD 21-44286109-C-T, REVEL 0.73, MetaLR 0.86
- H35L (p.His35Leu), gnomAD 21-44286110-A-T, REVEL 0.68, MetaLR 0.85
Public AIRE analysis runs
- AIRE analysis run — AIRE (1,149 variants) — completed 2026-08-19